FFI Ventures

𝐁𝐮𝐢𝐥𝐝 𝐄𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐖𝐡𝐚𝐭𝐬𝐀𝐩𝐩 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 In today's fast-paced life, effective communication is paramount. With WhatsApp Business, we enable our Partners in the Pharma Industry to reach their audiences with relevant, targeted, and compliant messages. Furthermore, it's beyond sending messages, as we open a direct line to the audience's most personal device. Supporting related projects—from omnichannel strategy orchestration and compliant consent management to campaign design, including content writing—the WhatsApp Business channel regularly outperforms traditional digital channels like email newsletters, with average read rates higher than 80%. It's a powerful tool in realizing the omnichannel ambition of delivering the right content to the right audience through the right channel at precisely the right time. Don't let your valuable messages get lost in crowded inboxes. Reach out now and put your communications at your audience's fingertips, exactly when and where they need them most. #HealthcareCommunications #WhatsAppBusiness #Omnichannel #Pharma

Is your organization planning to initiate or expand its AI use to achieve next year’s objectives? We're excited to announce our upcoming webinar, "Return of Investment of AI" in collaboration with the swiss health quality association (shqa) and dedicated to colleagues in Swiss affiliates. Building on the success of the initial AI Forum in June, this webinar is part of the educational series designed specifically for pharma professionals by pharma experts. What we will discuss during the lunch webinar on November 5th: - Explore the AI use-case horizon across various functions - Get insights about efficient ROI calculation for AI projects - Learn about industry benchmarks - Get your questions answered by peers and receive a special offer   This webinar is tailored for a wide range of professionals, including: - General Managers - Commercial Function experts & Marketing teams - Medical, Market Access, and Regulatory professionals - Digital Leads Don't miss this opportunity to equip yourself with realistic value creating scenarios, supporting the budget proposals and AI projects with ambitious success metrics. Join us virtually on November 5th from 12:00 to 13:30 CET. Space is limited, please secure your spot now. Registration link in comments. #AIinPharma #PharmaceuticalInnovation #DigitalTransformation #SHQA

Exciting news! FFI Ventures is now an official Veeva AI Partner. This collaboration brings cutting-edge #AI solutions to the forefront of healthcare innovation in #Pharma, #Biotech & #Medtech. About FFI: As a Swiss-based boutique consulting company, we accelerate growth and transform patient care by providing strategic AI solutions and generative AI services to over 18 Pharma, biotech & medtech companies. Our #generativeAI private Healthcare platform OneRay.ai, co-created with Pharma companies, is revolutionizing the industry. This partnership marks a significant step forward in advancing AI-driven healthcare solutions! Read more about the opportunities here: https://lnkd.in/dYujZ8ew

With budget season due, how can life science companies use generative AI to free up budget. Benchmark with the best and benefit from their insights. Make sure to attend the 30' webinar on October 16.

Lets connect at BioTechX Europe 2024! 🧬🚀 We're looking forward to being part of the Europe’s largest pharmaceutical development and healthcare event. As we are at the forefront of the latest innovations and co-creating with the industry, we'd love to engage with fellow attendees! 🤝 Are you also attending BioTechX? Let's meet for a coffee and discuss: - Emerging trends in biotech and pharma - Potential synergies in the realm of Data, AI, Precision and Innovation - How our experts at FFI-Ventures can add value 📅 Drop a comment below or send us a DM to schedule a meet-up during the event. Looking forward to engaging conversations and see you soon! #BioTechXEurope2024 #Biotech #Networking #Innovation #Pharma

How do companies get value out of AI in Medical Affairs? With budget season upon most organizations, the questions about where to invest and how to deliver growth results or realize efficiencies are top of mind. Reflecting on 18 months with generative AI solutions and continued exchanges and discussions about yet more transformative potential of AI for medical, we see three takeaways for decision makers. 1.       Private generative AI can deliver high quality results for medical affairs Numerous use cases that we’ve been able to implement with pharma, medtech and biotech companies over the past 18 months demonstrate that reliable results can be delivered. Controlled, private large language model instances and clean data lay the foundation. It is possible to avoid and eliminate hallucinations and have clear visibility and linkage back to the source reference documents. Continued healthy skepticism is warranted, as #AracelisTorres observed last week in a webinar. 2.       Focus on the business pain points Organizations that focus on the pain points and less on the technology tend to identify more relevant use cases. Whether the issue is rapidly building capabilities without massive investment or hiring, managing peaks and troughs in the business, or capturing efficiencies because more must be done with less – gaining clarity about the business needs sets the more effective companies apart. While 3 criteria are usually sufficient to prioritize the use cases, some organizations prefer to use up to 15. Based on the estimated benefit, the complexity to implement, and the time horizon, the most attractive use cases are then identified. We see companies achieving triple digit ROI and payback periods of 3-6 months. 3.       Making technology available is not correlated to results in Medical Affairs Many organizations are making private instances of publicly available large language models available within their controlled environment. The results are often mixed and of limited value, leading to a slow uptake and missed expectations. As Mayo Clinic learned with their pilot of generative ai that produced mixed results, supporting users by defining a controlled setting and specific tasks is more likely to produce productive results. We see organizations capture more value when clearly defined low to medium complexity tasks such as literature tracking and summaries, lay person summaries, reference validations are tackled first. This allows people to build expertise and adjust their workflow while building capabilities. Contact us to discuss your business needs in Medical Affairs. #mayoclinic #medicalaffairs #generativeAI #AracelisTorres

We're building AI-powered solutions to create submission dossiers for the authorities in Pharma, Biotech & Medtech. We often see a level of scepticism on this type of solutions in the community. Share your optinion with us!

Early Diagnosis in Rare Diseases: The Power of Technology   In the complex world of rare diseases, early diagnosis is both critical and challenging. With over 7,000 known rare diseases affecting millions worldwide, the need for innovative diagnostic approaches has never been greater. At FFI Ventures, we collaborate closely with life-science industry partners to leverage cutting-edge technology to revolutionize this landscape.   The Early Diagnosis Challenge   Identifying rare disease patients often poses significant hurdles: - Subtle or nonspecific initial symptoms - Limited awareness among primary care physicians - Lack of comprehensive screening programs   These factors can lead to the "diagnostic odyssey," with patients waiting years for accurate diagnosis. For example, hemophilia A affects 1 in every 5,000 male births, yet early identification is difficult without a known family history.   Harnessing Technology to Shorten Time to Diagnosis   To reduce the time it takes to diagnose rare diseases, we need to leverage strategic partnerships, engage all relevant stakeholders, and utilize technology across various channels. This collaborative approach will help drive faster, more accurate diagnoses and improve patient outcomes.   - Raise Awareness: Implement targeted education programs for HCPs, focusing on specific diagnostic steps for rare diseases. Use a high-impact omni-channel approach to ensure that HCPs are well-equipped to recognize early signs of these diseases. - Leverage Digital/AI Tools: Leverage AI-powered platforms to assist HCPs in narrowing down potential diagnoses based on symptom patterns. Integrate these tools into clinical workflows to support real-time, accurate decision-making. - Build Specialist Networks: Establish virtual networks for rapid access to expert opinions and peer-to-peer education among rare disease specialists. - Empower Patients: Provide patients with digital resources for symptom tracking, early disease identification, and guidance on seeking specialized care.   Our team, with extensive experience in rare disease product commercialization, collaborates with key stakeholders – from KOLs to patient advocacy groups – to drive these innovations forward.   At FFI Ventures, we're here to support these initiatives and work alongside the medical community to illuminate the path toward early diagnosis and enhanced patient care.   #RareDisease #EarlyDiagnosis #HealthTech #AIinHealthcare #FFIVentures #DigitalTools

Key Opinion Leaders (KOLs) are crucial in shaping medical practices and influencing treatment decisions within the healthcare industry. Their expertise and influence can be instrumental in establishing therapeutic concepts, improving treatment visibility, and gaining valuable insights. Identifying KOLs involves considering factors such as scientific leadership, patient impact, and engagement potential. Pharma, Biotech, and MedTech companies assess KOLs' publications, presentations, research contributions, and track record of improving patient outcomes. Their social media presence and willingness to collaborate with potential industry partners can help assess the engagement potential. Organizations are finding that prioritizing KOLs based on strategic alignment and engagement potential is essential. Data quality drives informed decisions about KOL engagement. A one-size-fits-all approach is often ineffective. Understanding the patient journey and targeting KOLs in regions with high concentrations of treaters can yield better results, and data-driven algorithms provide valuable insights. Organizations that tailor their approach as a function of the specific therapeutic area and markets achieve superior outcomes. Identifying and engaging with the right KOLs can significantly impact your organization's success. Contact us to explore how we can help you develop a tailored strategy that aligns with your goals and produces results together with KOLs in your therapeutic and geographic areas.